A5026702759- RNA modifications and cancer
- Pancreatic and Hepatic Oncology Research
- Autophagy in Disease and Therapy
- Cancer-related Molecular Pathways
- Cancer, Hypoxia, and Metabolism
- Traditional Chinese Medicine Analysis
- Flavonoids in Medical Research
- Metal-Organic Frameworks: Synthesis and Applications
- Chemical Synthesis and Analysis
- Reproductive System and Pregnancy
- Peroxisome Proliferator-Activated Receptors
- Inflammatory Biomarkers in Disease Prognosis
- Endometrial and Cervical Cancer Treatments
- Chronic Lymphocytic Leukemia Research
- Mitochondrial Function and Pathology
- Neurological Disease Mechanisms and Treatments
- Epigenetics and DNA Methylation
- Cancer, Stress, Anesthesia, and Immune Response
- Ferroptosis and cancer prognosis
- Cancer-related gene regulation
- Bioactive Compounds and Antitumor Agents
Third Affiliated Hospital of Zhengzhou University
2024
Zhengzhou University
2019-2023
China-US (Henan) Hormel Cancer Institute
2021
Abstract Esophageal squamous cell carcinoma (ESCC) is an upper gastrointestinal cancer with high morbidity and mortality. New strategies are urgently needed to prolong patients’ survival. Through screening FDA-approved drugs, we found dasabuvir, a drug approved for hepatitis C virus (HCV) treatment, suppressed ESCC proliferation. Dasabuvir could inhibit the growth of cells in time dose-dependent manner arrested cycle at G0/G1 phase. The antitumor activity was further validated vivo using...
Esophageal squamous cell carcinoma (ESCC) has a worldwide impact on human health, due to its high incidence and mortality. Therefore, identifying compounds increase patients' survival rate is urgently needed. Mefloquine (MQ) FDA-approved anti-malarial drug, which been reported inhibit cellular proliferation in several cancers. However, the anti-tumor activities of drug have not yet completely defined. In this study, mass spectrometry was employed profile proteome changes ESCC cells after MQ...
Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the two major types of cancer (EC). ESCC accounts for 90% EC. Recurrence after primary treatment is main reason poor survival. Therefore, recurrence prevention a promising strategy extending 5-year survival rate. Here, we found tegaserod maleate could inhibit proliferation both in vivo vitro . Proteomics analysis revealed that suppressed peroxisome signaling pathway, which key molecules membrane protein 11B...
Abstract Esophageal squamous cell carcinoma (ESCC), a malignant neoplasm with high incidence, is severe global public health threat. The current modalities used for treating ESCC include surgery, chemotherapy, and radiotherapy. Although management treatment strategies have improved over the last decade, overall 5-year survival rate remains <20%. Therefore, identification of novel therapeutic that can increase patient rates urgently needed. Oxethazaine, an amino-amide anesthetic agent,...
Background Early natural menopause, characterized by the cessation of ovarian function before age 45, has been a subject prior research indicating that inflammation may predict onset menopause. However, specific relationship between peripheral blood inflammatory parameters and early menopause remains ambiguous. Methods This observational study utilized data from National Health Nutrition Examination Survey (NHANES) spanning years 2013–2018. The at was ascertained through Reproductive...
We aimed to explore the inhibitory effects of Scutellaria barbata D. Don (skullcap) aqueous extract (SBE) on growth and migration lung cancer cells analyze underlying mechanism via bioinformatics analysis. SBE effectively inhibited proliferation adenocarcinoma A549 assessed by experimental study. Wogonin is one active ingredients SBE, its target, CDK1, was selected network pharmacology. CDK1 expression greater in (LUAD) tissues than normal according GEPIA2 UALCAN related progression...
Abstract Esophageal squamous cell carcinoma (ESCC) is an upper gastrointestinal cancer with high morbidity and mortality. New strategies are urgently needed to prolong patients’ survival. Through screening of FDA-approved drugs, we found dasabuvir, a drug approved for hepatitis C virus (HCV) treatment, suppresses ESCC proliferation. Dasabuvir could inhibit the growth cells in time dose-dependent manner arrested cycle at G0/G1 phase. The antitumor activity was further validated vivo using...
Background: Esophageal squamous cell carcinoma (ESCC) still has high rates of incidence and mortality, despite developments in medical technology. Therefore, looking for cancer treatment drugs with efficiency low toxicity remains very important. In the previous study, we screened FDA-approved drugs, approved uses other than tumor treatment, found that mefloquine (MQ), which is used prevention malaria, inhibited clone formation ESCC cells.Methods: Proteomics mass spectrometry (MS) were...
Abstract Background: Esophageal squamous cell carcinoma (ESCC) is a high recurrence rate of upper-digestive cancer with low 5-year survival rate. Therefore, there an urgent need for effective chemopreventive drugs that can extend the patients. Through screening FDA-approved drugs, dasabuvir was found to suppress ESCC proliferation. Methods: Cell number count assay used screen inhibitory effect on cells and detect proliferation KYSE150 KYE450. Phosphoproteomics proteomics were investigate...